AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9137509
Drug: MMV chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with medroxyprogesterone acetate
Trial: 9137509
Drug: MMV chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMV chemotherapy (mitomycin C, methotrexate, vincristine) with prednisolone
Trial: 8106223
Drug: 6mg buccal
RxNorm normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6mg buccal prochlorperazine one hour before surgery
Trial: 28715811
Drug: Ranibizumab treatment
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab treatment (3-month scheduled followed by 9-month pro re nata)
Trial: 23621388
Drug: Matrix rhythm
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix rhythm therapy
Trial: 19076173
Drug: New classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New classes of oral anticoagulants (e.g., dabigatran, rivaroxiban)
Trial: 15338504
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg qd
Trial: 16960941
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg qd
Trial: 12631041
Drug: i.v. propacetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. propacetamol 40 mg kg(‐1)
Trial: 12631041
Drug: i.v. propacetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. propacetamol 20 mg kg(‐1)
Trial: 12631041
Drug: i.v. propacetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. propacetamol 10 mg kg(‐1)
Trial: 12631041
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (H, I, L)
Trial: 11789281
Drug: Angelica sinensis
RxNorm normalized name: ANGELICA SINENSIS ROOT
DrugBank: Angelica sinensis root (DB14336)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angelica sinensis injection
Trial: 11789281
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose injection
Trial: 7682581
Drug: Correlation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation with immunoglobulin G levels
Trial: 2001826
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg ranitidine at night
Trial: 9412912
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine twice daily
Trial: 26661319
Drug: Metoprolol CR/XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/XL up-titrated to 200 mg/day
Trial: 19608185
Drug: Probiotic strain
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic strain L. plantarum (DSM 9843)
Trial: 15690537
Drug: Tac /
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tac / steroids
Trial: 11871829
Drug: Methylprednisolone acetate
RxNorm normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate (80 mg intramuscularly once weekly for 6 weeks)
Trial: 11871829
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (40 mg/day in a 'tailing‐off' regimen)
Trial: 9647268
Drug: Salmeterol 42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 42 microg via metered-dose inhaler twice daily
Trial: 11206232
Drug: Albuterol 180
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol 180 microg four times daily
Trial: 2493023
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg, orally)
Trial: 31192625
Drug: Experimental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatments using logarithmic‐transformed ANOVA (LANOVA) and logarithmic‐transformed ANCOVA (LANCOVA)
Trial: 28427388
Drug: Standard Speech
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Speech Therapy (SST) for 45 minutes, twice a week for 9 months
Trial: 28427388
Drug: Movement, Cognition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Movement, Cognition and Narration of emotions treatment (MCNT) for 3 hours per day, 5 days a week for 9 months
Trial: 28427388
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list for Standard Speech Therapy (SST) for 9 months
Trial: 25256361
Drug: Dialogical exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialogical exposure group treatment using Gestalt empty‐chair method
Trial: 25256361
Drug: Supportive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive group treatment
Trial: 25256361
Drug: Dialogical exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialogical exposure group treatment
Trial: 21439633
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (loading dose 1 g over 10 min followed by infusion of 1 g over 8 h)
Trial: 12918131
Drug: Regimen 2
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 2 (saccharomyces boulardii 250 mg Tid + metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Trial: 12918131
Drug: Regimen 1
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen 1 (metronidazole 750 mg Tid + iodoquinol 630 mg Tid for 10 days)
Trial: 19659665
Drug: Allopurinol mouth
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Allopurinol mouth rinse (1 mg/ml)
Trial: 10604042
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 120 mg/d
Trial: 10604042
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 240 mg/d
Trial: 8770319
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg once daily for 6 weeks)
Trial: 8770319
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg once daily for 6 weeks)
Trial: 1682226
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg D,L-kawain
Trial: 1682226
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg D,L-kawain
Trial: 1682226
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg D,L-kawain
Trial: 6958484
Drug: Budesonide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (100 micrograms daily)
Trial: 30245281
Drug: Acetaminophen 975
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 975 mg
Trial: 30245281
Drug: Ibuprofen 292.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 292.5 mg
Trial: 25230866
Drug: 3-hour extended
RxNorm normalized name: alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour extended infusion of meropenem (1 g dissolved in 40 mL saline, followed by 750 mg continuous infusion for 3 hours, repeated every 8 hours)
Trial: 25230866
Drug: 30-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion of meropenem (1 g dissolved in 40 mL saline, intravenous infusion within 30 minutes every 8 hours)
Trial: 25230866
Drug: 3-hour extended
RxNorm normalized name: alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour extended infusion of meropenem
Trial: 25230866
Drug: 30-minute infusion
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute infusion of meropenem
Trial: 20002472
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance tests (OGTT)
Trial: 17480223
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (No-MBP)
Trial: 14997083
Drug: Sufentanil (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil (0.01 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Trial: 14997083
Drug: Remifentanil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (0.1 microg/kg/min) with propofol (site‐effect 3.0 microg/ml)
Trial: 11642080
Drug: Diltiazem (120-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (120-180 mg twice a day)
Trial: 2480576
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 1000 mg/kg
Trial: 2480576
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 750 mg/kg
Trial: 25660106
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with 5 methyl‐aminolevulinate
Trial: 22968058
Drug: cutaneous lysate
RxNorm normalized name: Thermus thermophilus lysate
DrugBank: Thermus thermophilus lysate (DB11227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cutaneous lysate skin cream applied twice daily for 3 months
Trial: 15871655
Drug: Cost-effective therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effective therapy
Trial: 7890059
Drug: RU486 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU486 (50 mg daily for 6 months)
Trial: 2098016
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with insect venom
Trial: 28439893
Drug: Re-induction therapy
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-induction therapy (including fludarabine, cytarabine ± anthracyclines)
Trial: 28439893
Drug: Allogeneic stem
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic stem cell transplantation (SCT) as consolidation therapy after relapse
Trial: 28439893
Drug: No SCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No SCT as part of relapse therapy
Trial: 26022214
Drug: Partially defatted
RxNorm normalized name: rice bran, defatted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially defatted Granulated Brazil nut (GBN) 13 g per day (≈227.5 μg/day of selenium)
Trial: 19404724
Drug: Telephone-administered cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered cognitive behavioral therapy (CBT)
Trial: 15308881
Drug: Angiotensin‐converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin‐converting enzyme inhibitor therapy
Trial: 15308881
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure treatment strategy achieving 128/78 mm Hg (low blood pressure goal)
Trial: 10401453
Drug: Medication-free period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-free period (4 weeks)
Trial: 7674179
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (no surface treatment)
Trial: 7406949
Drug: Probucol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (4 X 250 mg per day for 4 months)
Trial: 25132461
Drug: Benzoyl peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benzoyl peroxide 3% topical gel
Trial: 22782343
Drug: Huachansu plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huachansu plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with huachansu 20 ml m(‐2) daily for 21 days)
Trial: 22782343
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus gemcitabine (gemcitabine 1000 mg m(‐2) on days 1, 8, and 15 with placebo)
Trial: 1973879
Drug: Phenoxybenzamine 140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine 140 mg/day (Group I)
Trial: 1973879
Drug: Phenoxybenzamine 270
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenoxybenzamine 270 mg/day (Group II)
Trial: 6273551
Drug: Otosporin (antibiotic/steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otosporin (antibiotic/steroid ear drops)
Trial: 27395330
Drug: Nutritional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional treatment + synbiotic (Lactobacillus and Bifidobacterium strains + 6 g fructooligosaccharides)
Trial: 27395330
Drug: Nutritional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional treatment + placebo (6 g maltodextrin)
Trial: 24862330
Drug: Aprepitant 125
RxNorm normalized name: aprepitant 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125 or 250 mg/d for 2 weeks
Trial: 24862330
Drug: Aprepitant 375,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 375, 625, 750, and 875 mg with exposure enhancement (EE)
Trial: 24862330
Drug: Aprepitant doses
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant doses of 875 mg (625 mg with EE) or higher
Trial: 19462434
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Calprotectin and Tumor M2-PK
Trial: 16624765
Drug: 20% intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% intralipid (500 ml once a day) from postburn day 4 for 10 consecutive days
Trial: 16624765
Drug: Non-intralipid treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intralipid treatment (control group)
Trial: 2005162
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (Control group, n=22)
Trial: 6407293
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of sustained-release nitroglycerin (SRNG)
Trial: 6407293
Drug: 6.5 mg
RxNorm normalized name: menthol 6.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg of sustained-release nitroglycerin (SRNG)
Trial: 30520243
Drug: Exenatide monotherapy
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide monotherapy
Trial: 28813878
Drug: Transcranial direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial direct current stimulation (tDCS) with wrist robot-assisted therapy
Trial: 28813878
Drug: Sham stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulation with wrist robot-assisted therapy
Trial: 24339309
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 μg/kg followed by 0.1 μg/kg/h until the end of surgery
Trial: 19173690
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg HES 130/0.42
Trial: 19173690
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg gelatin
Trial: 17502431
Drug: Indiplon (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indiplon (30, 50, and 80 mg)
Trial: 15143450
Drug: Theophylline (5-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5-7 mg/kg body weight)
Trial: 11435967
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg i.v. on days 0 and 4)
Trial: 9740480
Drug: valsartan 40
RxNorm normalized name: valsartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 40 mg twice daily
Trial: 21166600
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg twice daily
Trial: 9740480
Drug: valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 160 mg twice daily
Trial: 9740480
Drug: lisinopril 5/10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril 5/10 mg once daily
Trial: 8047822
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (weekend therapy)
Trial: 8047822
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg once daily (Italian study)
Trial: 8047822
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg once daily (weekend therapy, Italian study)
Trial: 28656129
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (amoxicillin + clarithromycin + omeprazole)
Trial: 28656129
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy plus Bifidobacterium lactis B94 (5 × 10^9 CFU/dose) plus inulin (900 mg) for 14 days
Trial: 28656129
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy plus Bifidobacterium lactis B94 plus inulin
Trial: 26076572
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic infiltration (7ml of local anesthetic: 4 ml of 0.25% bupivacaine and 3 ml of 2% lidocaine)
Trial: 21426271
Drug: Bleaching with
RxNorm normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching with White Smile, treatment with ascorbic acid and bonding with composite resin (G2)
Trial: 21426271
Drug: Bleaching with
RxNorm normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching with Opalesence, treatment with ascorbic acid and bonding with composite resin (G5)
Trial: 19767078
Drug: C1 esterase
RxNorm normalized name: C1 esterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor concentrate at a dose of 20 U/kg
Trial: 19767078
Drug: C1 esterase
RxNorm normalized name: C1 esterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor concentrate at a dose of 10 U/kg
Trial: 12584828
Drug: Oxymatrine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine 0.4 g/d by intramuscular injection for 3 months
Trial: 12584828
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (liver protecting agents)
Trial: 12584828
Drug: Oxymatrine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymatrine treatment
Trial: 8521190
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (0.1 IU/kg/day s.c.)
Trial: 2156644
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of bendrofluazide plus inhaled salbutamol (1 mg doses)
Trial: 2156644
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of bendrofluazide plus potassium, magnesium, or triamterene plus inhaled salbutamol (1 mg doses)
Trial: 2156644
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of bendrofluazide plus 50 mg of triamterene plus inhaled salbutamol (1 mg doses)
Trial: 2156644
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus inhaled salbutamol (1 mg doses)
Trial: 6249334
Drug: Guanfacine 3
RxNorm normalized name: guanfacine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 3 mg
Trial: 28682286
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac (50 mg, taken twice daily for 3 days)
Trial: 28682286
Drug: Transdermal diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal diclofenac (100 mg, placed once daily for 3 days)
Trial: 21554549
Drug: udenafil 200
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: udenafil 200 mg
Trial: 15521893
Drug: linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linezolid (600 mg)
Trial: 15521893
Drug: moclobemide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moclobemide (300 mg)
Trial: 2878942
Drug: Chlorpromazine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (30 mg)